Regeneron Pharmaceuticals (REGN) Getting Somewhat Positive Press Coverage, Report Shows
Media stories about Regeneron Pharmaceuticals (NASDAQ:REGN) have been trending somewhat positive on Friday, Accern reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Regeneron Pharmaceuticals earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 44.3756832036536 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Regeneron Pharmaceuticals, Inc. (REGN) Director Sells $712,500.00 in Stock (americanbankingnews.com)
- Why Regeneron Pharmaceuticals Dropped 11.3% in September (fool.com)
- Insider Selling: Regeneron Pharmaceuticals, Inc. (REGN) Director Sells 2,000 Shares of Stock (americanbankingnews.com)
- IP Attys Back Regeneron Over Inequitable Conduct Finding (law360.com)
- 10/02 Regeneron Pharmaceuticals, Inc. $REGN Position Boosted by L & S Advisors .. (4-traders.com)
REGN has been the subject of several research analyst reports. Zacks Investment Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 4th. Piper Jaffray Companies increased their price objective on Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the stock an “overweight” rating in a report on Tuesday, June 20th. BMO Capital Markets reiterated a “market perform” rating and issued a $484.00 price objective (up previously from $421.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. Leerink Swann reiterated an “outperform” rating and issued a $493.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, June 13th. Finally, Citigroup Inc. reiterated a “buy” rating and issued a $575.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, September 7th. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $487.26.
Shares of Regeneron Pharmaceuticals (REGN) opened at 463.40 on Friday. The company has a market cap of $49.14 billion, a price-to-earnings ratio of 46.49 and a beta of 1.62. The firm has a 50 day moving average price of $460.15 and a 200-day moving average price of $451.28. Regeneron Pharmaceuticals has a 12-month low of $325.35 and a 12-month high of $543.55.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating the consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The firm had revenue of $1.47 billion during the quarter, compared to analyst estimates of $1.36 billion. During the same quarter in the prior year, the business posted $2.82 EPS. The business’s revenue for the quarter was up 21.2% compared to the same quarter last year. On average, equities analysts expect that Regeneron Pharmaceuticals will post $14.93 earnings per share for the current fiscal year.
In other news, SVP Robert E. Landry sold 526 shares of the stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $472.19, for a total transaction of $248,371.94. Following the completion of the sale, the senior vice president now owns 9,099 shares in the company, valued at approximately $4,296,456.81. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Robert E. Landry sold 189 shares of the stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total value of $94,700.34. Following the sale, the chief financial officer now owns 10,099 shares of the company’s stock, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. In the last quarter, insiders have sold 89,468 shares of company stock valued at $42,312,448. Company insiders own 10.80% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/10/06/regeneron-pharmaceuticals-regn-getting-somewhat-positive-press-coverage-report-shows.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.